Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > OVs improve cancer immunotherapy by reprogramming TME

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 11, 2023 10:36am

122 Views

Post# 35777760

RE:RE:RE:OVs improve cancer immunotherapy by reprogramming TME

McGroots , So tell me what you know about everything you've posted. Tell me about the lack of successes with each of the 'promising' agents that you've commented on, particularly the adenovirus LOAd703 and the CPI CTLA-4. Are you here to pump both? And what are the clinical results with each? Nil?

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas